About Actavis
Actavis is a company based in Parsippany Troy Hills (United States) founded in 1956 was acquired by Teva Pharmaceuticals in July 2015. Actavis has completed 7 acquisitions, including Allergan, Auden Mckenzie and Durata Therapeutics.
- Headquarter Parsippany Troy Hills, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$8.68 B (USD)47as on Dec 31, 2013
-
Net Profit
-$725.2 M (USD)-838as on Dec 31, 2013
-
EBITDA
-$398.8 M (USD)-226as on Dec 31, 2013
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Investments & Acquisitions
Allergan
& 6 more
-
Acquired by
Teva Pharmaceuticals
(Jul 27, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Actavis
Investors in Actavis
Actavis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Teva Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals.
|
Locked | Locked | Locked |
Investor details for Actavis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Actavis
Actavis has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Allergan, Auden Mckenzie and Durata Therapeutics.
Investment portfolio details for Actavis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Novel antibiotics for infectious diseases are developed by the company.
|
Locked | Locked | 2009 | Locked | |
|
Drug development for gastroenterology disorders is conducted.
|
Locked | Locked | 2009 | Locked | |
|
Developer of generic medicines
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Actavis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Actavis
Detailed financials for Actavis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Actavis Comparisons
Peer comparison for Actavis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Actavis
Detailed competitors of Actavis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Actavis
Complete news archive for Actavis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Actavis
Actavis was founded in 1956 and raised its 1st funding round 58 years after it was founded.
Actavis is headquartered in Parsippany Troy Hills, United States. It is registered at Parsippany Troy Hills, New Jersey, United States.
Annual revenue of Actavis is $8.68B as on Dec 31, 2013.
Actavis was founded in 1956 and is headquartered in Parsippany Troy Hills, United States. Operations focus on the pharmaceutical sector, with emphasis on generic drug production and distribution. The company acquired Allergan, leading to a name change to Allergan plc, though the U.S. and Canadian generics business continues under the Actavis brand. In 2013, annual revenues reached 5.91 billion, alongside a net profit of 0.09 billion.
Actavis has made 7 acquisitions, including Allergan, Auden Mckenzie, and Durata Therapeutics.
Actavis has 1 investor. Key investors include Teva Pharmaceuticals.